Compare ZBH & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZBH | MEDP |
|---|---|---|
| Founded | 1927 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 15.4B |
| IPO Year | 2001 | 2016 |
| Metric | ZBH | MEDP |
|---|---|---|
| Price | $92.24 | $592.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 21 | 12 |
| Target Price | $101.00 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 2.0M | 356.4K |
| Earning Date | 04-28-2026 | 04-22-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | 1.22 | ★ 8.53 |
| Revenue | ★ $8,231,500,000.00 | N/A |
| Revenue This Year | $4.96 | $13.19 |
| Revenue Next Year | $3.76 | $7.75 |
| P/E Ratio | $75.47 | ★ $69.09 |
| Revenue Growth | ★ 7.20 | N/A |
| 52 Week Low | $79.12 | $373.00 |
| 52 Week High | $108.29 | $677.90 |
| Indicator | ZBH | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 71.47 |
| Support Level | $85.21 | $577.01 |
| Resistance Level | $96.45 | $622.32 |
| Average True Range (ATR) | 2.58 | 20.72 |
| MACD | 0.00 | 4.15 |
| Stochastic Oscillator | 69.62 | 50.47 |
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.